Milan
,
Italy
5 - 8 June 2024
The International Liver Congress (EASL Congress 2024)
Presentation schedule and materials
Wednesday, 05 June 2024
08:30
CEST
LBP-032
Publication
Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis – a subgroup analysis from the SELECT trial
Sebastian M. Meyhöfer1,2; Bertrand Cariou3; Cintia Cercato4; Helen M. Colhoun5; Anne Katrine Duun-Henriksen6; Iris Kliers6; A. Michael Lincoff7; Ildiko Lingvay8; Michelle T. Long6,9; Philip Newsome10; Stephen J. Nicholls11; Maria De Los Angeles Quiroga Pelaez6; Ferruccio Santini12; Arun J. Sanyal13; Steven E. Kahn14 On behalf of the SELECT investigator group
08:30
CEST
LBP-003
Publication
Semaglutide achieves resolution of metabolic dysfunction-associated steatohepatitis via modulation of multiple pathogenic pathways: insights from human and animal studies
Jara M1; Norlin J2; Kjær MS1; Almholt K2; Bendtsen KM2; Bugianesi E3; Cusi K4; Galsgaard ED2; Geybels M5; Gluud LL6; Harder LM2; Loomba R7; Mazzoni G2; Newsome PN8,9; Nitze LM1; Palle MS5; Ratziu V10; Sejling A-S1; Wong VW11; Anstee QM12,13; Knudsen LB2
08:30
- 18:00
CEST
WED-138
Publication
Patients with alpha-1-antitrypsin deficiency and the risk of developing liver events: A longitudinal cohort study
Pavel Strnad1; Tina Landsvig Berentzen2; Louise Maymann Nitze2; Klaus Kaae Andersen2; Kamal Kant Mangla3; Michael Soliman4; Mohamed Tawfik2; Alice Turner5
08:30
- 18:00
CEST
WED-275
Publication
BARRIERS–MASLD: Understanding barriers to adoption of clinical guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) among hepatologists in Europe
Laurent Castera1; William Alazawi2; Elisabetta Bugianesi3; Cyrielle Caussy4; Massimo Federici5; Manuel Romero-Gomez6; Jörn M. Schattenberg7; Ron Basuroy8; Dmitry Estulin9; Jeffrey V. Lazarus10,13
Friday, 07 June 2024
08:30
- 18:00
CEST
FRI-233
Publication
Cardiovascular disease burden in patients with and without metabolic dysfunction-associated steatohepatitis: data from the unCoVer-MASH longitudinal cohort study
Elisabetta Bugianesi1; Anurag Mehta2; Kamal Kant Mangla3; Abhishek Shankar Chandramouli4; Katrine Grau3; Niels Krarup3; Ahsan Shoeb Patel3
Saturday, 08 June 2024
08:30
- 17:00
CEST
SAT-201
Publication
Phase 3 ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests
Philip N. Newsome1,2; Elisabetta Bugianesi3; Vlad Ratziu4; Mary E. Rinella5; Michael Roden6,7,8; Kristiane A. Engebretsen9; Iris Kliers9; Laura Harms Østergaard9; Denise Vanni9; Jeppe Zacho9; Arun Sanyal10
Keywords